Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria + tetanus + pertussis (acellular) + poliomyelitis (inactivated) + haemophilus influenzae type b vaccine
- Development stage
- Approved
- Lead developer
- Sanofi Pasteur
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
DTaP-IPV-Hib is a pentavalent combination vaccine designed for active immunization against five major childhood diseases: diphtheria, tetanus, pertussis (whooping cough), poliomyelitis (polio), and invasive diseases caused by Haemophilus influenzae type b (Hib). The vaccine typically consists of diphtheria and tetanus toxoids, acellular pertussis antigens (including pertussis toxoid and filamentous hemagglutinin), inactivated poliovirus (types 1, 2, and 3), and the Hib capsular polysaccharide (polyribosylribitol phosphate) conjugated to a protein carrier such as tetanus toxoid. By combining these components into a single injection, the vaccine simplifies pediatric immunization schedules and improves compliance. It is widely used in national immunization programs and has been studied for potential non-specific effects on the immune system, such as its association with the development of atopic dermatitis in infants.
- Brand names
- PentacelPentaximInfanrix IPV+Hib
- Other names
- DTaP-IPV-HibDTaP-IPV/HibPentavalent vaccine (DTaP-IPV-Hib)
02
Targets
CD4+ T-cell receptorMHC II (Major histocompatibility complex class II receptor)
Beyond the preview
Go deeper on diphtheria + tetanus + pertussis (acellular) + poliomyelitis (inactivated) + haemophilus influenzae type b vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria + tetanus + pertussis (acellular) + poliomyelitis (inactivated) + haemophilus influenzae type b vaccine.